Blog
RSS FeedPosted by Michael Wonder on 30 Dec 2015
Agenda for the 6 January 2016 TC meeting
31 December 2015 - The Transparency Commission will consider the reimbursement of adalimumab (Humira), delamanid (Deltyba), panobinostat lactate (Farydak), lenalidomide (Revlimid) ...
Posted by Michael Wonder on 28 Dec 2015
NICE issues revised draft guidance on ezetimibe for hypercholesterolaemia
24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...
Posted by Michael Wonder on 23 Dec 2015
Agenda for the March 2016 PBAC meeting
23 December 2015 - The Agenda for the March 2016 PBAC meeting is now available. ...
Posted by Michael Wonder on 22 Dec 2015
Evolocumab: no hint of added clinical benefit according the IQWiG in Germany
15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...
Posted by Michael Wonder on 21 Dec 2015
SMC announces more forthcoming submissions
21 December 2015 - The SMC has announced forthcoming submissions for the following medicines: alendronic acid (Binosto), cabazitaxel (Jevtana), ibrutinib ...
Posted by Michael Wonder on 20 Dec 2015
Filgrastim and methotrexate prefilled syringe proposal with Novartis New Zealand Ltd
21 December 2015 - PHARMAC is seeking feedback on a proposal involving filgrastim and methotrexate prefilled syringes, resulting from a provisional ...
Posted by Michael Wonder on 20 Dec 2015
Recommendations made by the PBAC - November 2015
18 December 2015 - The recommendations from the November 2015 PBAC meeting are now available. ...
Posted by Michael Wonder on 18 Dec 2015
Changes to the conditions under which eculizumab may be prescribed on the PBS
18 December 2015 - The conditions under which eculizumab (Solaris ®) may be prescribed on the PBS change as of today. ...
Posted by Michael Wonder on 18 Dec 2015
F1 5% statutory price reductions on 1 April 2016 - list of affected drugs
18 December 2015 - The PBS Pricing Matters webpage has been updated to include a list of F1 drugs that meet ...
Posted by Michael Wonder on 16 Dec 2015
CADTH calls for feedback: anti–vascular endothelial growth factor drugs for retinal conditions
16 December 2015 - A draft recommendation on the anti–vascular endothelial growth factor drugs for retinal conditions is now available for ...
Posted by Michael Wonder on 16 Dec 2015
NICE recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
16 December 2015 - In final guidance as part of its Highly Specialised Technologies Programme, NICE has recommended Elosulfase alfa (Vimizin, ...
Posted by Michael Wonder on 16 Dec 2015
NICE issues guidance not recommending apremilast for psoriatic arthritis
16 December 2015 - NICE has published final guidance today which does not recommend apremilast (Otezla, Celgene) for adults with active ...
Posted by Michael Wonder on 16 Dec 2015
Kadcyla price too high for routine NHS funding, says NICE in final guidance
16 December 2015 - NICE has issued its final guidance on the use of Kadcyla (trastuzumab emtansine) as a treatment for ...
Posted by Michael Wonder on 16 Dec 2015
NICE says yes to dry eye disease treatment in final guidance
16 December 2015 - NICE has published final guidance recommending cyclosporin (Ikervis, Santen Pharmaceutical) for treating severe keratitis in adults with ...
Posted by Michael Wonder on 16 Dec 2015
PBS price disclosure 2016 April cycle outcomes summary
16 December 2015 - The summary of price disclosure price reductions for the 2016 April Cycle (Fourth SPD) has now been ...